$THC
TENET HEALTHCARE CORP Stock $thc

$thc Overview Financials Valuation SEC Filings Company Website

2010 Q4 Form 8-K Financial Statement

#000110465912066566 Filed on October 01, 2012

Income Statement

Concept	2010 Q4	2010	2009 Q4
Revenue	$2.111B	$8.265B	$2.261B
YoY Change	-6.63%	2.02%	3.86%
Cost Of Revenue	$394.0M	$1.577B	$394.0M
YoY Change	0.0%	0.51%	2.34%
Gross Profit	$1.717B	$6.890B	$1.867B
YoY Change	-8.03%	2.09%	4.19%
Gross Profit Margin	81.34%	83.36%	82.57%
Selling, General & Admin	$967.0M	$3.900B	$1.170B
YoY Change	-17.35%	1.11%	4.19%
% of Gross Profit	56.32%	56.6%	62.67%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$101.0M	$394.0M	$95.00M
YoY Change	6.32%	2.07%	1.06%
% of Gross Profit	5.88%	5.72%	5.09%
Operating Expenses	$1.537B	$6.234B	$1.744B
YoY Change	-11.87%	1.32%	3.44%
Operating Profit	$180.0M	$634.0M	$123.0M
YoY Change	46.34%	20.99%	16.04%
Interest Expense	-$101.0M	$424.0M	-$102.0M
YoY Change	-0.98%	-4.72%	-3.77%
% of Operating Profit	-56.11%	66.88%	-82.93%
Other Income/Expense, Net
YoY Change
Pretax Income	$62.00M	$158.0M	-$11.00M
YoY Change	-663.64%	-17.28%	37.5%
Income Tax	$2.000M	-$977.0M	-$33.00M
% Of Pretax Income	3.23%	-618.35%
Net Earnings	$80.00M	$1.152B	$25.00M
YoY Change	220.0%	484.77%	-175.76%
Net Earnings / Revenue	3.79%	13.94%	1.11%
Basic Earnings Per Share		$9.24
Diluted Earnings Per Share	$569.4K	$8.16	$199.8K
COMMON SHARES
Basic Shares Outstanding		121.1M shares
Diluted Shares Outstanding		140.2M shares

Balance Sheet

Concept	2010 Q4	2010	2009 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$406.0M	$406.0M	$703.0M
YoY Change	-42.25%	-42.25%	34.42%
Cash & Equivalents	$405.0M	$405.0M	$690.0M
Short-Term Investments	$1.000M	$1.000M	$13.00M
Other Short-Term Assets	$289.0M	$464.0M	$423.0M
YoY Change	-31.68%	9.69%	-37.98%
Inventory	$156.0M	$156.0M	$153.0M
Prepaid Expenses	$70.00M
Receivables	$1.143B	$1.143B	$1.158B
Other Receivables	$22.00M	$142.0M	$35.00M
Total Short-Term Assets	$2.311B	$2.311B	$2.472B
YoY Change	-6.51%	-6.51%	-8.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.304B	$4.304B	$4.313B
YoY Change	-0.21%	-0.21%	0.51%
Goodwill	$652.0M		$607.0M
YoY Change	7.41%
Intangibles
YoY Change
Long-Term Investments	$27.00M	$164.0M	$182.0M
YoY Change	-85.16%	-9.89%	-24.79%
Other Assets	$627.0M	$711.0M	$0.00
YoY Change		887.5%
Total Long-Term Assets	$6.189B	$6.189B	$5.481B
YoY Change	12.92%	12.92%	0.29%
TOTAL ASSETS
Total Short-Term Assets	$2.311B	$2.311B	$2.472B
Total Long-Term Assets	$6.189B	$6.189B	$5.481B
Total Assets	$8.500B	$8.500B	$7.953B
YoY Change	6.88%	6.88%	-2.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$720.0M	$720.0M	$739.0M
YoY Change	-2.57%	-2.57%	7.73%
Accrued Expenses	$486.0M	$486.0M	$573.0M
YoY Change	-15.18%	-15.18%	-18.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$67.00M	$67.00M	$2.000M
YoY Change	3250.0%	3250.0%	0.0%
Total Short-Term Liabilities	$1.725B	$1.725B	$1.783B
YoY Change	-3.25%	-3.25%	-8.52%
LONG-TERM LIABILITIES
Long-Term Debt	$3.997B	$3.997B	$4.272B
YoY Change	-6.44%	-6.44%	-10.59%
Other Long-Term Liabilities	$554.0M	$959.0M	$1.053B
YoY Change	-47.39%	-8.93%	-12.18%
Total Long-Term Liabilities	$554.0M	$4.956B	$5.325B
YoY Change	-89.6%	-6.93%	-10.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.725B	$1.725B	$1.783B
Total Long-Term Liabilities	$554.0M	$4.956B	$5.325B
Total Liabilities	$6.681B	$6.734B	$7.307B
YoY Change	-8.57%	-7.84%	-9.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.522B
YoY Change
Common Stock	$27.00M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.479B
YoY Change
Treasury Stock Shares	65.10M shares
Shareholders Equity	$1.766B	$1.766B	$646.0M
YoY Change
Total Liabilities & Shareholders Equity	$8.500B	$8.500B	$7.953B
YoY Change	6.88%	6.88%	-2.7%

Cashflow Statement

Concept	2010 Q4	2010	2009 Q4
OPERATING ACTIVITIES
Net Income	$80.00M	$1.152B	$25.00M
YoY Change	220.0%	484.77%	-175.76%
Depreciation, Depletion And Amortization	$101.0M	$394.0M	$95.00M
YoY Change	6.32%	2.07%	1.06%
Cash From Operating Activities	$175.0M	$472.0M	$141.0M
YoY Change	24.11%	11.06%	110.45%
INVESTING ACTIVITIES
Capital Expenditures	-$196.0M	-$463.0M	-$192.0M
YoY Change	2.08%	1.76%	47.69%
Acquisitions
YoY Change
Other Investing Activities	$47.00M	-$3.000M	$12.00M
YoY Change	291.67%	-400.0%	-79.66%
Cash From Investing Activities	-$149.0M	-$420.0M	-$180.0M
YoY Change	-17.22%	236.0%	153.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-19.00M	-$337.0M	-2.000M
YoY Change	850.0%	188.03%	100.0%
NET CHANGE
Cash From Operating Activities	175.0M	$472.0M	141.0M
Cash From Investing Activities	-149.0M	-$420.0M	-180.0M
Cash From Financing Activities	-19.00M	-$337.0M	-2.000M
Net Change In Cash	7.000M	-$285.0M	-41.00M
YoY Change	-117.07%	-255.74%	720.0%
FREE CASH FLOW
Cash From Operating Activities	$175.0M	$472.0M	$141.0M
Capital Expenditures	-$196.0M	-$463.0M	-$192.0M
Free Cash Flow	$371.0M	$935.0M	$333.0M
YoY Change	11.41%	6.25%	69.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	65098918	shares
CY2010Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	550882110	shares
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1050000000	shares
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2010Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2010Q4	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Issued PreferredStockSevenPercentMandatoryConvertibleSharesIssued	345000	shares
CY2010Q4	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.15
CY2010Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	302000000	USD
CY2010Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3100000000	USD
CY2010Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	352000000	USD
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	136442696	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	551468550	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1050000000	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2011Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2011Q4	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Issued PreferredStockSevenPercentMandatoryConvertibleSharesIssued	345000	shares
CY2011Q4	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.15
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	360000000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3386000000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	6954000000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1815000000	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	397000000	USD
CY2009	us-gaap	Share Based Compensation ShareBasedCompensation	23000000	USD
CY2010	thc	Payments To Acquire Property Plant And Equipment For Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentForContinuingOperations	433000000	USD
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	18000000	USD
CY2010	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9000000	USD
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8500000000	USD
CY2010Q4	us-gaap	Minority Interest MinorityInterest	53000000	USD
CY2010Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1479000000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1522000000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-43000000	USD
CY2010Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4449000000	USD
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	27000000	USD
CY2010Q4	us-gaap	Preferred Stock Value PreferredStockValue	334000000	USD
CY2010Q4	us-gaap	Liabilities Liabilities	6681000000	USD
CY2010Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	554000000	USD
CY2010Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	22000000	USD
CY2010Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	383000000	USD
CY2010Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3997000000	USD
CY2010Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1725000000	USD
CY2010Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	368000000	USD
CY2010Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	8000000	USD
CY2010Q4	us-gaap	Interest Payable Current InterestPayableCurrent	115000000	USD
CY2010Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	84000000	USD
CY2010Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	363000000	USD
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	720000000	USD
CY2010Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	67000000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8462000000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	1423000000	USD
CY2009	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	507277000	shares
CY2009	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	201000000	USD
CY2009	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2009	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
CY2009	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.42
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.04
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.03
CY2010	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.01
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.31
CY2009	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-20000000	USD
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
CY2010	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.27
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1108000000	USD
CY2009	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	10000000	USD
CY2009	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-17000000	USD
CY2009	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	8000000	USD
CY2009	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	12000000	USD
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	560631000	shares
CY2009	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	4000000	USD
CY2009	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23000000	USD
CY2009	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	191000000	USD
CY2009	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	15000000	USD
CY2009	us-gaap	Interest Expense InterestExpense	445000000	USD
CY2009	us-gaap	Operating Income Loss OperatingIncomeLoss	524000000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	9000000	USD
CY2009	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	27000000	USD
CY2009	us-gaap	Depreciation And Amortization DepreciationAndAmortization	373000000	USD
CY2009	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1831000000	USD
CY2009	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1534000000	USD
CY2009	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3781000000	USD
CY2010	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1101000000	USD
CY2009	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	480240000	shares
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	484321000	shares
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	17000000	USD
CY2009	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	183000000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1141000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-7000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Before Tax Period Increase Decrease OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecrease	-18000000	USD
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1000000	USD
CY2010	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Period Increase Decrease OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecrease	-20000000	USD
CY2009	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Period Increase Decrease OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecrease	-3000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	497000000	USD
CY2009	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	7000000	USD
CY2009	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	46000000	USD
CY2009	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	885000000	USD
CY2009	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1291000000	USD
CY2009	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-125000000	USD
CY2009	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1000000	USD
CY2009	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	49000000	USD
CY2009	thc	Distributions Received From Reclassification Of Reserve Fund DistributionsReceivedFromReclassificationOfReserveFund	12000000	USD
CY2009	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17000000	USD
CY2009	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	67000000	USD
CY2009	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	221000000	USD
CY2009	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	11000000	USD
CY2009	thc	Construction Of New And Replacement Hospitals ConstructionOfNewAndReplacementHospitals	58000000	USD
CY2009	thc	Payments To Acquire Property Plant And Equipment For Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentForContinuingOperations	387000000	USD
CY2009	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	425000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-9000000	USD
CY2010	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	1000000	USD
CY2010	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	11000000	USD
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-977000000	USD
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	158000000	USD
CY2010	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-57000000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	634000000	USD
CY2010	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	10000000	USD
CY2010	us-gaap	Depreciation And Amortization DepreciationAndAmortization	380000000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	653000000	USD
CY2010	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1857000000	USD
CY2010	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1542000000	USD
CY2010	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3830000000	USD
CY2011	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8654000000	USD
CY2009	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.37
CY2009	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.04
CY2009	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.41
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-292000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-286000000	USD
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	374000000	USD
CY2009	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-117000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-503000000	USD
CY2009	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	8000000	USD
CY2009	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	68000000	USD
CY2011	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	4000000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2000000	USD
CY2009	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-13000000	USD
CY2009	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15000000	USD
CY2009	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	78000000	USD
CY2009	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	24000000	USD
CY2009	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	635000000	USD
CY2009	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-9000000	USD
CY2009	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	27000000	USD
CY2009	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20000000	USD
CY2009	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-43000000	USD
CY2010	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	34000000	USD
CY2010	us-gaap	Interest Paid Net InterestPaidNet	-402000000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	690000000	USD
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-285000000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-337000000	USD
CY2010	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	7000000	USD
CY2009	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	39000000	USD
CY2010	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	8000000	USD
CY2010	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	24000000	USD
CY2010	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	27000000	USD
CY2010	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	601000000	USD
CY2010	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	886000000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-420000000	USD
CY2010	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-2000000	USD
CY2010	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-15000000	USD
CY2009	us-gaap	Interest Paid Net InterestPaidNet	-439000000	USD
CY2010	thc	Distributions Received From Reclassification Of Reserve Fund DistributionsReceivedFromReclassificationOfReserveFund	1000000	USD
CY2010	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	84000000	USD
CY2011Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	204000000	USD
CY2010	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24000000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011	dei	Amendment Flag AmendmentFlag	false
CY2010	us-gaap	Profit Loss ProfitLoss	1152000000	USD
CY2009	us-gaap	Profit Loss ProfitLoss	197000000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1492000000	USD
CY2010	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	19000000	USD
CY2010	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	65000000	USD
CY2010	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	30000000	USD
CY2010	thc	Construction Of New And Replacement Hospitals ConstructionOfNewAndReplacementHospitals	13000000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	472000000	USD
CY2010	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-58000000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-87000000	USD
CY2010	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-3000000	USD
CY2010	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	15000000	USD
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	731000000	USD
CY2010	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	10000000	USD
CY2010	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	31000000	USD
CY2008Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	507000000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	22000000	USD
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-952000000	USD
CY2011	dei	Entity Registrant Name EntityRegistrantName	TENET HEALTHCARE CORP
CY2011	dei	Entity Central Index Key EntityCentralIndexKey	0000070318
CY2011	dei	Document Type DocumentType	8-K
CY2011	dei	Document Period End Date DocumentPeriodEndDate	2011-12-31
CY2009	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000000	USD
CY2009	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	334000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	-11000000	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1819000000	USD
CY2010	us-gaap	Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	-1000000	USD
CY2011	us-gaap	Profit Loss ProfitLoss	94000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	85000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	49000000	USD
CY2010	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	8992000000	USD
CY2009	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	8785000000	USD
CY2011	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	9371000000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	58000000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1119000000	USD
CY2009	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	181000000	USD
CY2010	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	83000000	USD
CY2009	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	192000000	USD
CY2008Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	147000000	USD
CY2009	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	7000000	USD
CY2009	us-gaap	Minority Interest Increase From Stock Issuance MinorityInterestIncreaseFromStockIssuance	4000000	USD
CY2009	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	334000000	USD
CY2009	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23000000	USD
CY2009Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	697000000	USD
CY2010	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	8000000	USD
CY2010	us-gaap	Minority Interest Increase From Stock Issuance MinorityInterestIncreaseFromStockIssuance	1000000	USD
CY2010	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12000000	USD
CY2011Q4	thc	Deferred Tax Assets Other Long Term Liabilities DeferredTaxAssetsOtherLongTermLiabilities	53000000	USD
CY2011	us-gaap	Future Amortization Expense Year Four FutureAmortizationExpenseYearFour	52000000	USD
CY2011	us-gaap	Future Amortization Expense Year Five FutureAmortizationExpenseYearFive	51000000	USD
CY2011	us-gaap	Future Amortization Expense After Year Five FutureAmortizationExpenseAfterYearFive	195000000	USD
CY2010Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49000000	USD
CY2010Q4	thc	Land Held For Expansion Long Term Receivables And Other Assets Noncurrent LandHeldForExpansionLongTermReceivablesAndOtherAssetsNoncurrent	44000000	USD
CY2011Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	22000000	USD
CY2011Q4	us-gaap	Equity Method Investments EquityMethodInvestments	23000000	USD
CY2010	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	45000000	USD
CY2011	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	90000000	USD
CY2011	us-gaap	Finite Lived Intangible Assets Future Amortization Expense FiniteLivedIntangibleAssetsFutureAmortizationExpense	489000000	USD
CY2011	us-gaap	Future Amortization Expense Year One FutureAmortizationExpenseYearOne	69000000	USD
CY2011	us-gaap	Future Amortization Expense Year Two FutureAmortizationExpenseYearTwo	63000000	USD
CY2011	us-gaap	Future Amortization Expense Year Three FutureAmortizationExpenseYearThree	59000000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-1000000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	42000000	USD
CY2010	us-gaap	Other Comprehensive Income Reclassification Of Defined Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Tax OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostTax	8000000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-1000000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	51000000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-52000000	USD
CY2011	us-gaap	Other Comprehensive Income Reclassification Of Defined Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Tax OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostTax	7000000	USD
CY2010Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	26000000	USD
CY2010Q4	us-gaap	Equity Method Investments EquityMethodInvestments	27000000	USD
CY2010Q4	us-gaap	Long Term Investments LongTermInvestments	53000000	USD
CY2010Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	18000000	USD
CY2011Q4	us-gaap	Long Term Investments LongTermInvestments	45000000	USD
CY2011Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	18000000	USD
CY2011Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	47000000	USD
CY2011Q4	thc	Land Held For Expansion Long Term Receivables And Other Assets Noncurrent LandHeldForExpansionLongTermReceivablesAndOtherAssetsNoncurrent	46000000	USD
CY2010Q4	us-gaap	Goodwill Gross GoodwillGross	3076000000	USD
CY2010Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	2424000000	USD
CY2009Q4	us-gaap	Goodwill Gross GoodwillGross	3031000000	USD
CY2009Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	2424000000	USD
CY2009Q4	us-gaap	Goodwill Goodwill	607000000	USD
CY2011Q4	us-gaap	Goodwill Gross GoodwillGross	3166000000	USD
CY2011Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	2430000000	USD
CY2010Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	744000000	USD
CY2010Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	442000000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	849000000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	489000000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7404000000	USD
CY2010	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	91000000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7736000000	USD
CY2011	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	109000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	178000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance	197000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	190000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	31000000	USD
CY2011Q4	thc	Deferred Tax Assets Investments And Other Assets DeferredTaxAssetsInvestmentsAndOtherAssets	5000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	695000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	44000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	41000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1439000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1378000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	153000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance	217000000	USD
CY2010Q4	thc	Deferred Tax Assets Other Long Term Liabilities DeferredTaxAssetsOtherLongTermLiabilities	52000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	185000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	14000000	USD
CY2010Q4	thc	Deferred Tax Assets Investments And Other Assets DeferredTaxAssetsInvestmentsAndOtherAssets	4000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	842000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	83000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	46000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1600000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1534000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	418000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	53000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	115000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	586000000	USD
CY2010Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	469000000	USD
CY2010Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	53000000	USD
CY2010Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	103000000	USD
CY2010Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	625000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	792000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	909000000	USD
CY2010	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1060000000	USD
CY2008Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78000000	USD
CY2009Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	46000000	USD
CY2009	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	20000000	USD
CY2009	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2000000	USD
CY2009	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	12000000	USD
CY2009	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2000000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	35000000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	12000000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	23000000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1000000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	35000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	15000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	12000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	4000000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	23000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	1000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	9000000	USD
CY2011Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	9000000	USD
CY2009	thc	Membership Interest Percentage MembershipInterestPercentage	0.50	pure
CY2010Q4	thc	Physician And Group Coverage Guarantees Current PhysicianAndGroupCoverageGuaranteesCurrent	70000000	USD
CY2010Q4	thc	Disproportionate Share Hospital Revenue Receivables Current DisproportionateShareHospitalRevenueReceivablesCurrent	33000000	USD
CY2010Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	249000000	USD
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	398000000	USD
CY2011	us-gaap	Interest Expense InterestExpense	375000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	164000000	USD
CY2010	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8265000000	USD
CY2009	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8101000000	USD
CY2011	thc	Defined Contribution Plan Employee Contribution Percentage Minimum DefinedContributionPlanEmployeeContributionPercentageMinimum	0.01	pure
CY2011	thc	Defined Contribution Plan Employee Contribution Percentage Maximum DefinedContributionPlanEmployeeContributionPercentageMaximum	0.75	pure
CY2009Q1	thc	Defined Contribution Plan Requisite Working Period Per Year Minimum DefinedContributionPlanRequisiteWorkingPeriodPerYearMinimum	1000
CY2009Q1	thc	Defined Contribution Plan Employer Matching Contribution Before Reduction DefinedContributionPlanEmployerMatchingContributionBeforeReduction	0.03	pure
CY2009Q4	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	16000000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	32000000	USD
CY2010	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	26000000	USD
CY2009	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	43000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	268000000	USD
CY2010Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	249000000	USD
CY2011	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2000000	USD
CY2010	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2000000	USD
CY2011	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14000000	USD
CY2010	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14000000	USD
CY2011	us-gaap	Defined Benefit Plan Actuarial Net Gains Losses DefinedBenefitPlanActuarialNetGainsLosses	-19000000	USD
CY2010	us-gaap	Defined Benefit Plan Actuarial Net Gains Losses DefinedBenefitPlanActuarialNetGainsLosses	-21000000	USD
CY2011	us-gaap	Defined Benefit Plan Benefits Paid DefinedBenefitPlanBenefitsPaid	18000000	USD
CY2010	us-gaap	Defined Benefit Plan Benefits Paid DefinedBenefitPlanBenefitsPaid	18000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	0	USD
CY2010Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	0	USD
CY2011Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-285000000	USD
CY2011Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	20000000	USD
CY2010Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	19000000	USD
CY2011Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	265000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	65000000	USD
CY2010Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	49000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-220000000	USD
CY2010Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-219000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0500	pure
CY2010Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0550	pure
CY2011Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0300	pure
CY2010Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0300	pure
CY2011Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	280000000	USD
CY2010Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	265000000	USD
CY2011	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	0	USD
CY2009	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	3000000	USD
CY2011	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-3000000	USD
CY2010	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-1000000	USD
CY2009	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-1000000	USD
CY2011	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	19000000	USD
CY2010	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	17000000	USD
CY2009	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	19000000	USD
CY2011	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0550	pure
CY2010	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0575	pure
CY2009	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0575	pure
CY2011	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0300	pure
CY2010	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0300	pure
CY2009	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0400	pure
CY2011Q4	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	16000000	USD
CY2010Q4	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	20000000	USD
CY2009Q4	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	3000000	USD
CY2011	us-gaap	Other Comprehensive Income Reclassification Of Defined Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Before Tax OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax	-19000000	USD
CY2010	us-gaap	Other Comprehensive Income Reclassification Of Defined Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Before Tax OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax	-21000000	USD
CY2009	us-gaap	Other Comprehensive Income Reclassification Of Defined Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Before Tax OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax	-7000000	USD
CY2009	us-gaap	Other Comprehensive Income Amortization Of Defined Benefit Plan Net Prior Service Cost Credit Recognized In Net Periodic Benefit Cost Before Tax OtherComprehensiveIncomeAmortizationOfDefinedBenefitPlanNetPriorServiceCostCreditRecognizedInNetPeriodicBenefitCostBeforeTax	3000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-65000000	USD
CY2010Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-49000000	USD
CY2009Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-29000000	USD
CY2011	thc	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Percentage Of Total ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentageOfTotal	1.000	pure
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33993572	shares
CY2011	thc	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage	1.000	pure
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	73000000	USD
CY2011Q4	thc	Physician Receivables And Relocation Agreements Current PhysicianReceivablesAndRelocationAgreementsCurrent	58000000	USD
CY2011Q4	thc	Physician And Group Coverage Guarantees Current PhysicianAndGroupCoverageGuaranteesCurrent	104000000	USD
CY2011Q4	thc	Disproportionate Share Hospital Revenue Receivables Current DisproportionateShareHospitalRevenueReceivablesCurrent	27000000	USD
CY2011Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2000000	USD
CY2011Q4	thc	Sublease Receivables Current SubleaseReceivablesCurrent	2000000	USD
CY2010Q4	thc	Sublease Receivables Current SubleaseReceivablesCurrent	2000000	USD
CY2011Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	36000000	USD
CY2011Q4	us-gaap	Financing Receivable Recorded Investment Equal To Greater Than90 Days Past Due FinancingReceivableRecordedInvestmentEqualToGreaterThan90DaysPastDue	38000000	USD
CY2010Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2000000	USD
CY2009	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-53000000	USD
CY2010Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	70000000	USD
CY2010Q4	thc	Physician Receivables And Relocation Agreements Current PhysicianReceivablesAndRelocationAgreementsCurrent	62000000	USD
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-6000000	USD
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6000000	USD
CY2010Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	28000000	USD
CY2010Q4	us-gaap	Financing Receivable Recorded Investment Equal To Greater Than90 Days Past Due FinancingReceivableRecordedInvestmentEqualToGreaterThan90DaysPastDue	17000000	USD
CY2011Q4	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	104000000	USD
CY2010Q4	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	87000000	USD
CY2010	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2010Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2009	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2011Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	33993572	shares
CY2011Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm1	5.3
CY2011Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.26
CY2011Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	26798092	shares
CY2011Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	7.53
CY2010Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-268000000	USD
CY2010	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	0	USD
CY2009	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2011	thc	Number Of Licensed Beds In Hospitals Operated By Subsidiaries NumberOfLicensedBedsInHospitalsOperatedBySubsidiaries	13453	bed
CY2011	thc	Number Of States In Which Subsidiaries Of Entity Operate Hospitals NumberOfStatesInWhichSubsidiariesOfEntityOperateHospitals	11	state
CY2011	thc	Number Of Free Standing And Provider Based Diagnostic Imaging Centers And Ambulatory Surgery Centers Operated By Subsidiaries NumberOfFreeStandingAndProviderBasedDiagnosticImagingCentersAndAmbulatorySurgeryCentersOperatedBySubsidiaries	98	center
CY2011	thc	Number Of Academic Medical Centers Operated By Subsidiaries NumberOfAcademicMedicalCentersOperatedBySubsidiaries	4	center
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-6000000	USD
CY2009	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000000	USD
CY2010	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6000000	USD
CY2009	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-42000000	USD
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	62000000	USD
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5000000	USD
CY2010	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-929000000	USD
CY2009	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	17000000	USD
CY2010	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-54000000	USD
CY2009	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2000000	USD
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	81000000	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	61000000	USD
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	57000000	USD
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	10000000	USD
CY2010	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	55000000	USD
CY2009	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-110000000	USD
CY2011Q4	thc	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive	82000000	USD
CY2011	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-12000000	USD
CY2011	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	-7000000	USD
CY2011	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	5000000	USD
CY2009	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-24000000	USD
CY2009	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	37000000	USD
CY2009	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	1000000	USD
CY2009	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1000000	USD
CY2011Q4	thc	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo	226000000	USD
CY2011Q4	thc	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree	67000000	USD
CY2011Q4	us-gaap	Restructuring Reserve RestructuringReserve	11000000	USD
CY2011	us-gaap	Restructuring Reserve Period Expense RestructuringReservePeriodExpense	13000000	USD
CY2011	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	11000000	USD
CY2011	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-1000000	USD
CY2011	thc	Cash Payments To Be Applied Against Accruals Due Within One Year CashPaymentsToBeAppliedAgainstAccrualsDueWithinOneYear	5000000	USD
CY2011	thc	Cash Payments To Be Applied Against Accruals Due Thereafter CashPaymentsToBeAppliedAgainstAccrualsDueThereafter	6000000	USD
CY2011Q4	thc	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour	476000000	USD
CY2010	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	10000000	USD
CY2010	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	3000000	USD
CY2010	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1054000000	USD
CY2010	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	16000000	USD
CY2010	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	3000000	USD
CY2010	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2000000	USD
CY2009	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	67000000	USD
CY2009	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	10000000	USD
CY2009	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	3000000	USD
CY2011Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	32000000	USD
CY2011Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	129000000	USD
CY2010Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	6000000	USD
CY2010Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	197000000	USD
CY2011Q4	thc	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Next Twelve Months LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	66000000	USD
CY2011Q4	thc	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal After Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive	3572000000	USD
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	416000000	USD
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	109000000	USD
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	99000000	USD
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	59000000	USD
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	40000000	USD
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	30000000	USD
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	79000000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	143000000	USD
CY2011	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	8000000	USD
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	134000000	USD
CY2009	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	141000000	USD
CY2010	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	12000000	USD
CY2009	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	17000000	USD
CY2009	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	27037000	shares
CY2010	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.26
CY2009	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.01
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1125000000	USD
CY2011Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	238000000	USD
CY2011Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	295000000	USD
CY2011Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	328000000	USD
CY2011Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	328000000	USD
CY2009	us-gaap	Loss Contingency Accrual Carrying Value Provision LossContingencyAccrualCarryingValueProvision	31000000	USD
CY2011Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	7333568	shares
CY2011Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	24014543	shares
CY2011Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	11326556	shares
CY2011Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	5354419	shares
CY2011Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	6882130	shares
CY2011Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	11464429	shares
CY2011Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	4582299	shares
CY2011	thc	Stock Repurchase Program Expiration Date StockRepurchaseProgramExpirationDate	09-May-12
CY2011Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	4.63
CY2011Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	5.15
CY2011Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	5.02
CY2011Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	6.16
CY2011Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	6.17
CY2011Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	6.28
CY2011Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	6.44
CY2011Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	204000000	USD
CY2011Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	370000000	USD
CY2011	thc	Allowance For Doubtful Accounts Lookback Period Used As Basis For Estimate AllowanceForDoubtfulAccountsLookbackPeriodUsedAsBasisForEstimate	18
CY2010	thc	Allowance For Doubtful Accounts Lookback Period Used As Basis For Estimate AllowanceForDoubtfulAccountsLookbackPeriodUsedAsBasisForEstimate	18
CY2010Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	30000000	USD
CY2011Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	66000000	USD
CY2011	us-gaap	Loss Contingency Accrual Carrying Value Provision LossContingencyAccrualCarryingValueProvision	72000000	USD
CY2010	us-gaap	Loss Contingency Accrual Carrying Value Provision LossContingencyAccrualCarryingValueProvision	12000000	USD
CY2011	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	36000000	USD
CY2010	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	78000000	USD
CY2009	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	181000000	USD
CY2011	thc	Legal Costs And Transfers Other LegalCostsAndTransfersOther	0	USD
CY2010	thc	Legal Costs And Transfers Other LegalCostsAndTransfersOther	1000000	USD
CY2009	thc	Legal Costs And Transfers Other LegalCostsAndTransfersOther	5000000	USD
CY2009Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	95000000	USD
CY2008Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	240000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	68000000	USD
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	468726000	shares
CY2011	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.14
CY2010	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	24000000	USD
CY2011	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Net Operating Revenues Before Provision for Doubtful Accounts</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our</font><font style="FONT-SIZE: 10pt" size="2"> <i>Compact with Uninsured Patients </i>(“Compact”).</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop-loss payments). Because Medicare requires that a hospital’s gross charges be the same for all patients (regardless of payer category), gross charges are also what hospitals charge all other patients prior to the application of discounts and allowances.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Revenues under the traditional fee-for-service Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost-based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense, which are based on our hospitals’ cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates recorded by us could change by material amounts.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">We have a system and estimation process for recording Medicare net patient revenue and estimated cost report settlements. This results in us recording accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity, and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted. Adjustments for prior-year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the years ended December 31, 2011, 2010 and 2009 by $1 million, $1 million and $5 million, respectively. Estimated cost report settlements and valuation allowances are deducted from accounts receivable in the accompanying Consolidated Balance Sheets (see Note 3). We believe that we have made adequate provision for any adjustments that may result from final determination of amounts earned under all the above arrangements with Medicare and Medicaid.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms as well as payment history. Although we do not separately accumulate and disclose the aggregate amount of adjustments to the estimated reimbursement for every patient bill, we believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of individual patient bills that were material to our revenues. In addition, on a corporate-wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for these payers and other factors that affect the estimation process.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">We know of no material claims, disputes or unsettled matters with any payer that would affect our revenues for which we have not adequately provided for in the accompanying Consolidated Financial Statements.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Under our Compact, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for self-pay accounts and other factors that affect the estimation process.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">We also provide charity care to patients who are financially unable to pay for the health care services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues or in provision for doubtful accounts. Patient advocates from our Medical Eligibility Program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 41%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="41%" colspan="8"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Years Ended December 31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2010</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2009</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Medicare</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,068</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,050</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,100</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Medicaid</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">802</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">740</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">677</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Managed care</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">5,128</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4,897</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4,773</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Indemnity, self-pay and other</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">958</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">954</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">917</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Acute care hospitals other revenue</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">105</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">115</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">118</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other operations</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">310</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">236</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">200</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Net operating revenues before provision for doubtful accounts</font></b><font style="FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">9,371</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">8,992</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">8,785</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></b></p></td></tr></table></td></tr></table>
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	485181000	shares
CY2011	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.14
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13685000	shares
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20171000	shares
CY2009	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	6000000	USD
CY2011	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	16455000	shares
CY2010	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	76310000	shares
CY2009	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26843000	shares
CY2010	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	3000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-10000000	USD
CY2011	us-gaap	Use Of Estimates UseOfEstimates	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Use of Estimates</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements, in conformity with accounting principles generally accepted in the United States of America (“GAAP”), requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.</font></p></td></tr></table>
CY2009	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	9000000	USD
CY2011	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.0135	pure
CY2011Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	100000000	USD
CY2011Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	26000000	USD
CY2010	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.0271	pure
CY2011Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	26000000	USD
CY2011	thc	Period For Use Of Ehr Technology To Become Eligible For Annual Medicare Incentive Payments PeriodForUseOfEHRTechnologyToBecomeEligibleForAnnualMedicareIncentivePayments	4	period
CY2011Q4	us-gaap	Other Receivables OtherReceivables	47000000	USD
CY2010	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	4000000	USD
CY2011	thc	Cost Report Filing Period After End Of Annual Cost Reporting Period CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod	5
CY2011	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	1000000	USD
CY2010	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	1000000	USD
CY2009	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	5000000	USD
CY2011	thc	Percentage Of Medicaid Incentive Payments Federally Funded PercentageOfMedicaidIncentivePaymentsFederallyFunded	1.00	pure
CY2011Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	252000000	USD
CY2010Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	243000000	USD
CY2011Q4	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	92000000	USD
CY2010Q4	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	109000000	USD
CY2011Q4	thc	Repatriated Cash From Subsidiaries RepatriatedCashFromSubsidiaries	21000000	USD
CY2011	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	23000000	USD
CY2011	thc	Property Plant And Equipment Additions Minimum Useful Life PropertyPlantAndEquipmentAdditionsMinimumUsefulLife	1
CY2011	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	8000000	USD
CY2009	us-gaap	Restructuring Charges RestructuringCharges	7000000	USD
CY2009	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	419000000	USD
CY2010	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	240000000	USD
CY2011	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	216000000	USD
CY2011	us-gaap	Insurance Recoveries InsuranceRecoveries	10000000	USD
CY2011	thc	Litigation Settlements Net Of Insurance Recoveries LitigationSettlementsNetOfInsuranceRecoveries	14000000	USD
CY2010Q4	us-gaap	Other Receivables OtherReceivables	22000000	USD
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2009	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2009	us-gaap	Restructuring Reserve Period Expense RestructuringReservePeriodExpense	11000000	USD
CY2009	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.977	pure
CY2009	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	23000000	USD
CY2009	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-1000000	USD
CY2010Q4	us-gaap	Restructuring Reserve RestructuringReserve	10000000	USD
CY2011	thc	Number Of Lawsuits NumberOfLawsuits	2	lawsuit
CY2011Q2	us-gaap	Stock Repurchase Program Authorized Amount StockRepurchaseProgramAuthorizedAmount	400000000	USD
CY2011Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	24259071	shares
CY2011Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	16027642	shares
CY2010	us-gaap	Restructuring Reserve Period Expense RestructuringReservePeriodExpense	1000000	USD
CY2010	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	5000000	USD
CY2011Q4	thc	Preferred Stock And Other Securities Held By Captive Insurance Subsidiaries PreferredStockAndOtherSecuritiesHeldByCaptiveInsuranceSubsidiaries	1000000	USD
CY2011Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	4.31
CY2011Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	4.42
CY2011Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	4.60
CY2011	thc	Defined Benefit Pension Plan Active Number DefinedBenefitPensionPlanActiveNumber	1	plan
CY2011	thc	Defined Benefit Pension Plan Frozen Number DefinedBenefitPensionPlanFrozenNumber	2	plan
CY2011	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	20000000	USD
CY2011Q4	us-gaap	Long Lived Assets Held For Sale Impairment Charge LongLivedAssetsHeldForSaleImpairmentCharge	12000000	USD
CY2010Q4	us-gaap	Long Lived Assets Held For Sale Impairment Charge LongLivedAssetsHeldForSaleImpairmentCharge	5000000	USD
CY2008Q4	us-gaap	Restructuring Reserve RestructuringReserve	27000000	USD
CY2009Q4	us-gaap	Restructuring Reserve RestructuringReserve	14000000	USD
CY2011Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.049	pure
CY2010Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.063	pure
CY2011	thc	Number Of Critical Access Hospitals Operated By Subsidiaries NumberOfCriticalAccessHospitalsOperatedBySubsidiaries	1	hospital
CY2011	thc	Cash And Cash Equivalents Maturity Period CashAndCashEquivalentsMaturityPeriod	3
CY2011	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.967	pure
CY2010	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.974	pure
CY2011Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	4360000000	USD
CY2010Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	4064000000	USD
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	66000000	USD
CY2011Q4	us-gaap	Minority Interest MinorityInterest	69000000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1440000000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1853000000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	1766000000	USD
CY2011	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4015000000	USD
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	4294000000	USD
CY2011	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	67000000	USD
CY2010	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-983000000	USD
CY2009	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	19000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	5000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	4000000	USD
CY2011	thc	Operating Loss Carryforward Limitation On Use Measurement Period OperatingLossCarryforwardLimitationOnUseMeasurementPeriod	3
CY2011	thc	Operating Loss Carryforward Limitation On Use Percent Of Shareholders OperatingLossCarryforwardLimitationOnUsePercentOfShareholders	0.05	pure
CY2011	thc	Incentive Payments For Technology Certification IncentivePaymentsForTechnologyCertification	55000000	USD
CY2011	thc	Provision For Doubtful Accounts Look Back Period ProvisionForDoubtfulAccountsLookBackPeriod	18
CY2011	thc	Property Plant And Equipment Additions Minimum Value PropertyPlantAndEquipmentAdditionsMinimumValue	500	USD
CY2011	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	4000000	USD
CY2009Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	46000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	35000000	USD
CY2011Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4489000000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113000000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	405000000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1278000000	USD
CY2010Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1143000000	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	161000000	USD
CY2010Q4	us-gaap	Inventory Net InventoryNet	156000000	USD
CY2011Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7000000	USD
CY2010Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	22000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	418000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	282000000	USD
CY2011Q4	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	2000000	USD
CY2010Q4	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	14000000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	378000000	USD
CY2010Q4	us-gaap	Other Assets Current OtherAssetsCurrent	289000000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	2357000000	USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	2311000000	USD
CY2011Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	156000000	USD
CY2010Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	164000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	374000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	627000000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4350000000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4304000000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	736000000	USD
CY2009	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	186000000	USD
CY2011	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1548000000	USD
CY2010Q4	us-gaap	Goodwill Goodwill	652000000	USD
CY2011	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2020000000	USD
CY2011	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-55000000	USD
CY2011	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-117000000	USD
CY2011Q4	us-gaap	Interest Payable Current InterestPayableCurrent	112000000	USD
CY2011Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	64000000	USD
CY2009	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	10000000	USD
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	362000000	USD
CY2011Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	337000000	USD
CY2011Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	2000000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	506000000	USD
CY2011Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000000	USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	334000000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	27000000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4407000000	USD
CY2011Q4	us-gaap	Assets Assets	8462000000	USD
CY2010Q4	us-gaap	Assets Assets	8500000000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	760000000	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	376000000	USD
CY2011Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	75000000	USD
CY2011	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-18000000	USD
CY2011	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	12000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2011	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	17000000	USD
CY2009	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-1000000	USD
CY2011	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-32000000	USD
CY2010	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-7000000	USD
CY2011	us-gaap	Gain Loss On Investments GainLossOnInvestments	3000000	USD
CY2010	us-gaap	Gain Loss On Investments GainLossOnInvestments	5000000	USD
CY2009	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	97000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	103000000	USD
CY2010	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1135000000	USD
CY2009	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	214000000	USD
CY2009	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	2000000	USD
CY2009	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	5000000	USD
CY2009	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	202000000	USD
CY2011	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Period Increase Decrease OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecrease	-15000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Before Tax Period Increase Decrease OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecrease	-15000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-6000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	-9000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	12000000	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2011	us-gaap	Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	0	USD
CY2009	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	3000000	USD
CY2011	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	365000000	USD
CY2011	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	3000000	USD
CY2009	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2011	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2009	us-gaap	Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	-7000000	USD
CY2009	us-gaap	Other Comprehensive Income Loss Before Tax Period Increase Decrease OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecrease	7000000	USD
CY2011	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	6000000	USD
CY2011	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2011	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
CY2010	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
CY2009	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2010	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	0	USD
CY2009	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	0	USD
CY2011	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	717000000	USD
CY2010	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	727000000	USD
CY2009	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	684000000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	24000000	USD
CY2011	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	30000000	USD
CY2011	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-41000000	USD
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	13000000	USD
CY2010	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5000000	USD
CY2009	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6000000	USD
CY2011	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2010	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-3000000	USD
CY2009	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1000000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	850000000	USD
CY2011	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	35000000	USD
CY2011	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	63000000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-32000000	USD
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-5000000	USD
CY2011	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	44000000	USD
CY2011	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-38000000	USD
CY2010	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	16000000	USD
CY2011	thc	Payments To Acquire Property Plant And Equipment For Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentForContinuingOperations	467000000	USD
CY2011	thc	Construction Of New And Replacement Hospitals ConstructionOfNewAndReplacementHospitals	0	USD
CY2011	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	8000000	USD
CY2011	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	84000000	USD
CY2009	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2011	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2011	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	59000000	USD
CY2011	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2010	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2011	thc	Distributions Received From Reclassification Of Reserve Fund DistributionsReceivedFromReclassificationOfReserveFund	0	USD
CY2011	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	USD
CY2010	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2009	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2010	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2009	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2011	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	445000000	USD
CY2010	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2009	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2011	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	843000000	USD
CY2011	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	900000000	USD
CY2011	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	21000000	USD
CY2010	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2010	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2011	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	24000000	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Continuing Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsContinuingOperations	2000000	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Discontinued Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsDiscontinuedOperations	19000000	USD
CY2009	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2011	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	10000000	USD
CY2011	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	6000000	USD
CY2011	us-gaap	Interest Paid Net InterestPaidNet	-347000000	USD
CY2011	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	30000000	USD
CY2011	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-10000000	USD
CY2010	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	0	USD
CY2011	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	10000000	USD
CY2011	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	14000000	USD
CY2011	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24000000	USD
CY2011	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	374000000	USD
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-18000000	USD
CY2010	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	0	USD
CY2010	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2009	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	0	USD
CY2010Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0	USD
CY2011	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2011	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	0.00
CY2011	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	0	USD
CY2010	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	0	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositions	21000000	USD
CY2010	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositions	58000000	USD
CY2010	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Continuing Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsContinuingOperations	45000000	USD
CY2010	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Discontinued Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsDiscontinuedOperations	13000000	USD
CY2011	thc	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense To Continuing Operations UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseToContinuingOperations	1000000	USD
CY2011	thc	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense To Discontinued Operations UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseToDiscontinuedOperations	2000000	USD
CY2011Q4	thc	Convertible Preferred Stock Principal Amount Denominator For Conversion Into Common Stock ConvertiblePreferredStockPrincipalAmountDenominatorForConversionIntoCommonStock	1000	USD
CY2012Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	5308179	shares
CY2011Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	40286713	shares
CY2011Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2011	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	75765585	shares
CY2011Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0.00
CY2011	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	4.94
CY2011Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	100000000	USD
CY2010Q4	us-gaap	Assets Held For Sale Long Lived AssetsHeldForSaleLongLived	25000000	USD
CY2011Q4	us-gaap	Assets Held For Sale Long Lived AssetsHeldForSaleLongLived	20000000	USD
CY2011Q4	thc	Electronic Health Record Incentives Receivable Current ElectronicHealthRecordIncentivesReceivableCurrent	13000000	USD
CY2010Q4	thc	Electronic Health Record Incentives Receivable Current ElectronicHealthRecordIncentivesReceivableCurrent	0	USD
CY2011	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	6000000	USD
CY2010	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2012Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	4.93
CY2011Q4	thc	Supplemental California Medical Payment Receivable Current SupplementalCaliforniaMedicalPaymentReceivableCurrent	16000000	USD
CY2011	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	108000000	USD
CY2010	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	56000000	USD
CY2009	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	88000000	USD
CY2011	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8000000	USD
CY2010	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5000000	USD
CY2010Q4	us-gaap	Litigation Reserve LitigationReserve	5000000	USD
CY2011	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	17000000	USD
CY2009	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-31000000	USD
CY2010	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-12000000	USD
CY2011	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-55000000	USD
CY2010Q4	thc	Supplemental California Medical Payment Receivable Current SupplementalCaliforniaMedicalPaymentReceivableCurrent	0	USD
CY2010Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1000000	USD
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1000000	USD
CY2011	thc	Number Of Free Standing Emergency Department NumberOfFreeStandingEmergencyDepartment	1	department
CY2009	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1000000	USD
CY2009	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14000000	USD
CY2009	thc	Increase Decrease In Long Lived Assets Estimated Fair Value IncreaseDecreaseInLongLivedAssetsEstimatedFairValue	3000000	USD
CY2012Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	26000000	USD
CY2011Q4	thc	Common Stock Fair Value Per Share CommonStockFairValuePerShare	5.13
CY2009Q1	thc	Defined Contribution Plan Employer Matching Contribution After Reduction DefinedContributionPlanEmployerMatchingContributionAfterReduction	0.015	pure
CY2011	thc	Number Of Hospitals Operated By Subsidiaries NumberOfHospitalsOperatedBySubsidiaries	50	hospital
CY2011	thc	Number Of Hospitals Owned By Subsidiaries NumberOfHospitalsOwnedBySubsidiaries	49	hospital
CY2011	thc	Number Of Academic Medical Centers Operated By The Subsidiaries NumberOfAcademicMedicalCentersOperatedByTheSubsidiaries	3	center
CY2011	thc	Number Of Licensed Beds In Hospitals Operated By The Subsidiaries NumberOfLicensedBedsInHospitalsOperatedByTheSubsidiaries	13119	bed
CY2011	thc	Number Of States In Which Subsidiaries Operate Hospitals NumberOfStatesInWhichSubsidiariesOperateHospitals	10	state
CY2011	thc	Number Of Hospitals To Which Segment Of The Entity Provides Revenue Cycle Services NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices	300	hospital
CY2011	thc	Capital Expenditure CapitalExpenditure	475000000	USD
CY2010	thc	Capital Expenditure CapitalExpenditure	476000000	USD
CY2009	thc	Capital Expenditure CapitalExpenditure	456000000	USD
CY2011	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-261000000	USD
CY2010	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-206000000	USD
CY2009	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-207000000	USD
CY2011	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1126000000	USD
CY2010	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1036000000	USD
CY2009	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	955000000	USD
CY2011	us-gaap	Asset Impairment Charges AssetImpairmentCharges	20000000	USD
CY2011	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	164000000	USD
CY2010	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10000000	USD
CY2010	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	158000000	USD
CY2009	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	191000000	USD
CY2009	us-gaap	Asset Impairment Charges AssetImpairmentCharges	27000000	USD
CY2011	thc	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2011	thc	Number Of Hospitals Classified In Discontinued Operations NumberOfHospitalsClassifiedInDiscontinuedOperations	1	hospital
CY2011	thc	Number Of States In Which Free Standing And Provider Based Diagnostic Imaging Centers And Ambulatory Surgery Centers Operated By Subsidiaries NumberOfStatesInWhichFreeStandingAndProviderBasedDiagnosticImagingCentersAndAmbulatorySurgeryCentersOperatedBySubsidiaries	12	state

Files In Submission

Name	View Source	Status
0001104659-12-066566-index-headers.html	Edgar Link	pending
0001104659-12-066566-index.html	Edgar Link	pending
0001104659-12-066566.txt	Edgar Link	pending
0001104659-12-066566-xbrl.zip	Edgar Link	pending
a12-19551_18k.htm	Edgar Link	pending
a12-19551_1ex23d1.htm	Edgar Link	pending
a12-19551_1ex99d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thc-20111231.xml	Edgar Link	completed
thc-20111231.xsd	Edgar Link	pending
thc-20111231_cal.xml	Edgar Link	unprocessable
thc-20111231_def.xml	Edgar Link	unprocessable
thc-20111231_lab.xml	Edgar Link	unprocessable
thc-20111231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THC
TENET HEALTHCARE CORP Stock $thc

2010 Q4 Form 8-K Financial Statement

#000110465912066566 Filed on October 01, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC TENET HEALTHCARE CORP Stock $thc

2010 Q4 Form 8-K Financial Statement

#000110465912066566 Filed on October 01, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC
TENET HEALTHCARE CORP Stock $thc